Zetrosaa Injection contains Aztreonam 1000mg, a monobactam antibiotic indicated for the treatment of serious Gram-negative bacterial infections. Aztreonam exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, specifically targeting penicillin-binding proteins in susceptible aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella species, and Proteus species. Zetrosaa Injection is primarily used in the management of lower respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, skin and soft tissue infections, and gynecological infections caused by susceptible organisms. It is administered intravenously or intramuscularly, allowing for rapid systemic distribution. The drug is particularly valuable in patients with penicillin allergies due to its minimal cross-reactivity with other beta-lactam antibiotics. Dosage and duration of therapy should be guided by the severity of infection, renal function, and microbial susceptibility patterns. Common adverse effects may include injection site reactions, gastrointestinal disturbances, and transient elevations in liver enzymes. Caution is advised in patients with renal impairment, and dosage adjustments may be necessary. Zetrosaa Injection should be used under strict medical supervision to ensure optimal therapeutic outcomes and minimize resistance development.